Efficacy and Long-term Safety of Oral Semaglutide Versus Sitagliptin in Subjects With Type 2 Diabetes (PIONEER 3)
This trial is conducted globally. The aim of the trial is to investigate efficacy and long-term safety of oral semaglutide versus sitagliptin in subjects with type 2 diabetes.
Study Type: Interventional (Clinical Trial)
Actual Enrollment: 1864 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: Efficacy and Long-term Safety of Oral Semaglutide Versus Sitagliptin in Subjects With Type 2 Diabetes
Actual Study Start Date: February 15, 2016
Actual Primary Completion Date: February 14, 2017
Actual Study Completion Date: March 28, 2018
Arm:
- Experimental: Semaglutide 3 mg
- Experimental: Semaglutide 7 mg
- Experimental: Semaglutide 14 mg
- Active Comparator: Sitagliptin 100 mg
| Category | Value |
|---|---|
| Date last updated at source | 2018-04-25 |
| Study type(s) | Interventional |
| Expected enrolment | 1864 |
| Study start date | 2016-02-15 |
| Estimated primary completion date | 2017-02-14 |